http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005079817-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_773d3f5ebb1d3e074ebe28411f1fa61a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1dd98ad4ee076841fec541542f952f58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1a1a86a59dcc45e4476632c50cea405a
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-727
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-727
filingDate 2005-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9366f791099072a21c43aa0a1c8fc2aa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86a57dc4fc8f64a2d8af2503639f1bc4
publicationDate 2005-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2005079817-A1
titleOfInvention Affinity purified heparin/heparan sulfate for controlling the biological activity of the fgf receptor
abstract Methods and compositions for modulating the activity of a FGF receptor in a mammal are disclosed. The methods and compositions utilize substantially purified heparin/heparan sulfate oligosaccharides (HS) that have high affinity for FGF7. HS that has high affinity for FGF7 has increased activity for promoting the formation of a ternary FGF/HS/FGFR complex. According to one embodiment of the invention, substantially purified HS is an octasaccharide having 7 or 8 sulfates and having predominant disaccharide composition of ΔHexA2SG1cN6S and a tri-sulfated disaccharide. Alternatively, the substantially purified HS is a longer oligosaccharide that contains an octasaccharide structural motif having 7 or 8 sulfates and having predominant disaccharide composition of ΔHexA2SG1cN6S and a tri-sulfated disaccharide.
priorityDate 2004-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002111331-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5034520-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9319096-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0140267-A2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21903340
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2723671
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3034366
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4766
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID441477
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID57199466
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID689043
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID50
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8272
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54289881
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409332
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5770
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226407902
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395489
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129452471
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128643097
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226411146
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399539
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395488
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129445658
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6235
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395003
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23073713
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7244
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226412103
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226402238
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226911956
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129192844
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226940259
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2518
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128994255

Total number of triples: 49.